ACCEL Lite: AHA Late-Breaker: SELECT – Semaglutide and CV Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes

The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM. In this interview, Abraham Lincoff, MD, FACC, and Glenn A. Hirsch MD, MHS, FACC, discuss AHA Late-Breaker: SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL